

Product datasheet for **TL311528V**

MDMX (MDM4) Human shRNA Lentiviral Particle (Locus ID 4194)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	MDMX (MDM4) Human shRNA Lentiviral Particle (Locus ID 4194)
Locus ID:	4194
Synonyms:	BMFS6; HDMX; MDMX; MRP1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	MDM4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001204171 , NM_001204172 , NM_001278516 , NM_001278517 , NM_001278518 , NM_001278519 , NM_002393 , NR_024171 , NM_002393.1 , NM_002393.2 , NM_002393.3 , NM_002393.4 , NM_001204172.1 , NM_001204171.1 , NM_001278518.1 , NM_001278516.1 , NM_001278519.1 , NM_001278517.1 , BC067299 , BC067299.1 , BC025993 , BC105106 , BC143431 , BC143432 , BM475824 , NM_002393.5
UniProt ID:	O15151
Summary:	This gene encodes a nuclear protein that contains a p53 binding domain at the N-terminus and a RING finger domain at the C-terminus, and shows structural similarity to p53-binding protein MDM2. Both proteins bind the p53 tumor suppressor protein and inhibit its activity, and have been shown to be overexpressed in a variety of human cancers. However, unlike MDM2 which degrades p53, this protein inhibits p53 by binding its transcriptional activation domain. This protein also interacts with MDM2 protein via the RING finger domain, and inhibits the latter's degradation. So this protein can reverse MDM2-targeted degradation of p53, while maintaining suppression of p53 transactivation and apoptotic functions. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Feb 2011]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).